| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 06/14/2000 | EP0845985B1 Non-steroidal sulfatase inhibitor compounds |
| 06/14/2000 | CN1053369C Pill for treating thyreoidism |
| 06/08/2000 | WO2000032775A1 Pth1r and pth3r receptors |
| 06/08/2000 | WO2000032771A1 Pth1r and pth3r receptors, methods and uses thereof |
| 06/08/2000 | WO2000032600A1 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 06/08/2000 | WO2000032222A1 Improvement of folliculogenesis |
| 06/08/2000 | WO2000032191A1 New pharmaceutical composition and the process for its preparation |
| 06/08/2000 | WO2000032178A2 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 06/08/2000 | WO2000015659A3 Stomach polypeptide zsig28 |
| 06/08/2000 | WO2000011191A3 Tpl-2/cot kinase and methods of use |
| 06/08/2000 | WO2000009086A3 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods |
| 06/08/2000 | CA2353085A1 Improvement of folliculogenesis |
| 06/08/2000 | CA2342621A1 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 06/07/2000 | EP1005490A1 Zinc free insulin crystals for use in pulmonary compositions |
| 06/07/2000 | EP1005484A1 Compounds with growth hormone releasing properties |
| 06/07/2000 | CN1255498A Process for prepn. of growth hormone stimulating secretion agent and its intermediate |
| 06/07/2000 | CN1053187C Derivatives of benzoylecgonine, ecgonine and ecgonidine and methods for preparing and using same |
| 06/06/2000 | US6071882 Administering an effective synergistic amount of leuteinizing hormone releasing hormone antagonist cetrorelix in combination with alpha-receptor blocking agents to treat the prostate hypertrophy and prostate cancer |
| 06/02/2000 | WO2000031267A1 Insulin production by engineered muscle cells |
| 06/02/2000 | WO2000031263A2 Gtpase associated proteins |
| 06/02/2000 | WO2000031136A1 Antagonistic analogs of gh-rh inhibiting igf-i and -ii |
| 06/02/2000 | WO2000031120A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 06/02/2000 | WO2000031084A1 Prostaglandin conjugates for treating or preventing bone disease |
| 06/02/2000 | WO2000031067A1 Propanoic acid derivatives as integrin inhibitors |
| 06/02/2000 | WO2000030674A1 Neuropeptide y y4 agents in the treatment of reproductive disorders |
| 06/02/2000 | WO2000030663A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 06/02/2000 | WO2000030624A2 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| 06/02/2000 | WO2000030623A2 Agent for lowering prolactin |
| 06/02/2000 | WO2000030622A2 Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases |
| 06/02/2000 | WO2000030615A1 Method of preparing stable suspensions of insoluble microparticles |
| 06/02/2000 | WO2000018388A3 Antibiotic compositions for treatment of the eye, ear and nose |
| 06/02/2000 | WO2000014236A3 Grf analogs with increased biological potency |
| 06/02/2000 | WO2000013650A3 Neuroprotection |
| 06/02/2000 | CA2352510A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 06/02/2000 | CA2352154A1 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| 06/02/2000 | CA2351679A1 Prostaglandin conjugates for treating or preventing bone disease |
| 06/02/2000 | CA2351361A1 Gtpase associated proteins |
| 06/02/2000 | CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 05/31/2000 | EP1004583A2 Process and hydantoin intermediates for the synthesis of growth hormone secretagogues |
| 05/31/2000 | EP1004306A2 Estrogen agonists/antagonists |
| 05/31/2000 | EP1003774A1 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 |
| 05/31/2000 | EP1003763A1 83 human secreted proteins |
| 05/31/2000 | EP1003744A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 05/31/2000 | EP1003737A1 Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists |
| 05/31/2000 | EP1003490A1 Transdermal therapeutic system (tts) for administering sexual steroid hormones |
| 05/31/2000 | EP0862551B1 Fluoro-substituted benzoylpropionic acid derivatives |
| 05/31/2000 | DE19853476A1 Prolaktin-senkendes Mittel Prolactin-lowering agent |
| 05/30/2000 | US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
| 05/25/2000 | WO2000029584A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/25/2000 | WO2000029583A2 Immunoglobulin superfamily proteins |
| 05/25/2000 | WO2000029380A1 Tetrahydroisoquinoline derivatives as lhrh antagonists |
| 05/25/2000 | WO2000029011A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/25/2000 | WO2000028970A1 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 05/25/2000 | DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
| 05/25/2000 | CA2350914A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/25/2000 | CA2347833A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/24/2000 | EP1002802A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1002799A1 Optically pure androgen mediator |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001797A1 Soya extract, process for its preparation and pharmaceutical composition |
| 05/24/2000 | CN1254347A Analogs of parathyroid hormone |
| 05/24/2000 | CN1052731C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052730C Compounds with growth hormone releasing properties |
| 05/23/2000 | US6066627 Steroids as neurochemical initiators of change in human blood levels of LH |
| 05/23/2000 | US6066475 Parathyroid cytosolic autoantigens recognized by autoantibodies from patients with acquired hypoparathyroidism |
| 05/18/2000 | WO2000027846A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027409A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells |
| 05/18/2000 | WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO2000007979A3 Compounds and compositions for delivering active agents |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2350642A1 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | CA2350235A1 Tricyclic pyrazole derivatives |
| 05/18/2000 | CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/17/2000 | EP1000085A1 Treatment of insulin resistance with growth hormone secretagogues |
| 05/17/2000 | EP1000066A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 05/17/2000 | EP1000008A1 Novel thyroid receptor ligands and method |
| 05/17/2000 | CN1253560A Sulfonamides for treatment of endothelin-mediated disorders |
| 05/17/2000 | CN1253503A Stabilized tibolone compositions |
| 05/16/2000 | US6063403 Compressed dry-granulation desogestrel tablets |
| 05/16/2000 | CA2170255C Pharmaceutical composition for immunoenhancement therapy |
| 05/16/2000 | CA1340994C Treatment of conditions and disease |
| 05/11/2000 | WO2000026252A1 Compounds with growth hormone releasing properties |
| 05/11/2000 | WO2000026243A2 Transmembrane 4 proteins |
| 05/11/2000 | WO2000026236A2 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function |
| 05/11/2000 | WO2000026227A1 Ldl related protein and uses thereof |
| 05/11/2000 | WO2000026216A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 05/11/2000 | WO2000025786A1 Heterocyclic potassium channel inhibitors |
| 05/11/2000 | WO2000025774A1 Benzamide potassium channel inhibitors |
| 05/11/2000 | WO2000025770A1 Carbocyclic potassium channel inhibitors |
| 05/11/2000 | CA2349567A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 05/11/2000 | CA2348446A1 Benzamide potassium channel inhibitors |
| 05/11/2000 | CA2347650A1 Transmembrane 4 proteins |
| 05/11/2000 | CA2347102A1 Compounds with growth hormone releasing properties |
| 05/11/2000 | CA2317117A1 Ldl related protein and uses thereof |